Loading…
Permanent OPTN Fee Authority Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2026 · third_quarter · Health Issues
Access to Genetic Counselor Services Act: H.R. 6280, S. 3607 Living Donor Protection Act: H.R. 4582, H.R 4583, S. 1552 Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2025: H.R. 1518. Restore Protections for Dialysis Patients Act: H.R. 2199; S. 1173. Permanent OPTN Fee Authority Act: H.R.5259; S. 2751. Kidney Care Access Protection Act: S.2730. H.R. 6214 Expanding Support for Living Donors Act: H.R. 7868 Improving Home Dialysis Act: H.R. 8875 CMS-1846-P: Medicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury Dialysis (AKI) Payment, and ESRD Quality Incentive Program Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program Medicaid Program; Community Engagement Requirement for Certain Individuals (CMS- 2454-IFC); Interim Final Rule with Comment Period
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $220,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Health Issues
Access to Genetic Counselor Services Act: H.R. 6280, S. 3607 Living Donor Protection Act: H.R. 4582, H.R 4583, S. 1552 Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2025: H.R. 1518. Restore Protections for Dialysis Patients Act: H.R. 2199; S. 1173. Permanent OPTN Fee Authority Act: H.R.5259; S. 2751. Kidney Care Access Protection Act: S.2730. H.R. 6214 Expanding Support for Living Donors Act: H.R. 7868 Improving Home Dialysis Act: H.R. 8875 Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (CMS-4212-P) Request for Information: Opportunities, Challenges, and Emerging Areas in Statistical Data, Analysis, and Research
Client expense: $240,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · first_quarter · Health Issues
Access to Genetic Counselor Services Act Living Donor Protection Act: H.R. 4582; H.R 4583; S. 1552 Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2025: H.R. 1518. Restore Protections for Dialysis Patients Act: H.R. 2199; S. 1173. Enhanced Advance Premium Tax Credits (eAPTCs) Permanent OPTN Fee Authority Act: H.R.5259; S. 2751. Kidney Care Access Protection Act: S.2730. H.R. 1 CMS-1830-P: End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model Proposed Local Coverage Determination (LCD) MolDX: Molecular Testing for Solid Organ Allograft Rejection Proposed LCD ID: DL40060 Proposed Local Coverage Determination (LCD) MolDX: Molecular Testing for Solid Organ Allograft Rejection Proposed LCD ID: DL40058
Client expense: $230,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · fourth_quarter · Health Issues
Access to Genetic Counselor Services Act Living Donor Protection Act: H.R. 4582; H.R 4583; S. 1552 Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2025: H.R. 1518. Restore Protections for Dialysis Patients Act: H.R. 2199; S. 1173. Enhanced Advance Premium Tax Credits (eAPTCs) Permanent OPTN Fee Authority Act: H.R.5259; S. 2751. Kidney Care Access Protection Act: S.2730. H.R. 1 CMS-1830-P: End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model Proposed Local Coverage Determination (LCD) MolDX: Molecular Testing for Solid Organ Allograft Rejection Proposed LCD ID: DL40060 Proposed Local Coverage Determination (LCD) MolDX: Molecular Testing for Solid Organ Allograft Rejection Proposed LCD ID: DL40058
Client expense: $170,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · third_quarter · Health Issues
Access to Genetic Counselor Services Act Living Donor Protection Act: H.R. 4582; H.R 4583; S. 1552 Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2025: H.R. 1518. Restore Protections for Dialysis Patients Act: H.R. 2199; S. 1173. Enhanced Advance Premium Tax Credits (eAPTCs) Permanent OPTN Fee Authority Act: H.R.5259; S. 2751. Kidney Care Access Protection Act: S.2730. H.R. 1 CMS-1830-P: End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model Proposed Local Coverage Determination (LCD) MolDX: Molecular Testing for Solid Organ Allograft Rejection Proposed LCD ID: DL40060 Proposed Local Coverage Determination (LCD) MolDX: Molecular Testing for Solid Organ Allograft Rejection Proposed LCD ID: DL40058
Client expense: $156,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
| HR 5259 |
119th |
| Identical bill |
| HR 1768 | 119th | Related bill |
| HR 1262 | 119th | Related bill |